The Daily Papule

Meeting abstracts

AAD 2026

American Academy of Dermatology · Denver, 27–31 March 2026

1,877 abstracts, published in JAAD on 6 July 2026. Their text is on the JAAD website.

  1. 70471

    Lower IL-17A levels in psoriasis patients treated with IL-23 inhibitors versus IL-17 inhibitors

    Minakawa S, Nakagawa J, … senior author Akasaka E

  2. 70550

    Methotrexate Use and Cardiovascular Risk in Psoriasis: A Multicenter Comparative Study from Sri Lanka

    Liyanage A, Liyanage G, … senior author Lekamwasam S

  3. 70619

    Inflammatory and Nutritional Predictors of High-Risk Psoriasis Phenotypes Identified by Machine Learning in the U.S. NHANES Cohort

    Gao V, Beheshti M, … senior author Ma J

  4. 70710

    Efficacy and safety of deucravacitinib in genital psoriasis: data from a phase 4 study

    Bissonnette R, Barker J, … senior author Gottlieb AB

  5. 71034

    Impact of Smoking Exposure and Cessation on Psoriasis Severity: Evidence from SPEECH Cohort

    Yu Q, Liang X, Shi Y

  6. 71091

    Real-world tildrakizumab effectiveness in the US by biologic experience and geographic region in the PPD CorEvitas Psoriasis Registry

    Lockshin B, Beeghly A, … senior author Prajapati VH

  7. 71092

    Sustained effectiveness of tildrakizumab in patients with moderate-to-severe psoriasis overall and in high-impact areas: 2-year results from the POSITIVE study

    Augustin M, Sommer R, … senior author Mrowietz U

  8. 71133

    Regulatory and Reimbursement Challenges for Wearable Phototherapy in Personalized Treatments for Psoriasis

    Multani H, Sraa K, … senior author Dempsey K

  9. 71162

    Psychiatric Risk Reduction in Psoriasis Patients Treated With GLP-1 Receptor Agonists

    Yan M, Chou P, … senior author Armstrong A

  10. 71184

    Biologic treatment in Psoriasis and Hidradenitis Suppurativa patients with active malignancy: Experience from a Tertiary Care Hospital

    Carrera Hernandez MJ, Martinez Lorenzo ER, … senior author Gomez Dorado BA

  11. 71204

    Associations of Outdoor Air Pollution Exposure and Psoriasis: a Systematic Review and Meta-Analysis of Epidemiologic Evidence

    Fadadu R, Jung A, … senior author Wei M

  12. 71498

    Efficacy of Apremilast in Patients With Mild to Moderate Psoriasis Involving the Scalp and Nails: A Post Hoc Analysis of the Phase 3 ADVANCE Study

    Gold LS, Gooderham M, … senior author Papp K

  13. 71660

    GLP-1 Receptor Agonist Use in Patients with Psoriasis or Hidradenitis Suppurativa

    Granovsky R, Bai A, … senior author Cobos G

  14. 71729

    Beyond Monotherapy: Synergistic TYK2 and IL-23 Inhibition for the Effective Management of Treatment-Resistant Psoriasis

    Visingardi J, Sherwood B, Simmons B

  15. 71835

    Efficacy and Safety of Janus Kinase Inhibitors vs Standard Therapy for Psoriatic Nail Disease: A Systematic Review and Meta-Analysis

    Martinez EC, Almeida Hidalgo JI, Floridia Rietman LM, et al.

  16. 71903

    Long-Term Real-World Effectiveness, Safety and Retention of Guselkumab in a Spanish Psoriasis Cohort: A Retrospective Study

    Bascón L, Muñoz-Santos C, Vidal AG

  17. 71957

    Comparative risk of psoriatic arthritis in psoriasis patients on immunomodulators

    Schmidt M, Dowdle T, … senior author Munoz A

  18. 71981

    Evidence-Based Biologic Selection for Moderate-to-Severe Psoriasis in Patients with IBD and Heart Failure

    Tognaccini C, Osborne S, … senior author Wu J

  19. 72064

    Early secukinumab treatment within the window of opportunity: a systematic review of its potential as a disease modifying strategy in the management of psoriatic disease

    Conrad C, Lalazi B, … senior author García Ruiz de Morales JM

  20. 72091

    SPECTREM: Guselkumab Skin Clearance and Patient-Reported Outcome Results Across Skin and Joint Symptoms Through Week 48 in Low Body Surface Area, Moderate Plaque Psoriasis With at Least One Moderate High-Impact Site Involved

    Gold LS, Papp KA, … senior author Lebwohl MG

  21. 72182

    The impact of deucravacitinib on health-related quality of life and fatigue in patients with psoriatic arthritis: pooled analysis of phase 3 trials in patients with active psoriatic arthritis

    Gottlieb AB, Mease PJ, … senior author Strand V

  22. 72255

    Synchronous teledermatology for patients with moderate to severe psoriasis in Pescadores Islands: Bridging health divides and geographical disparities

    Wang TT, Lee CH

  23. 72304

    Sequential Switching Between Ustekinumab Biosimilars in Psoriasis: Real-World Evidence of Clinical Interchangeability

    De Luca DA, Papara C, … senior author Thaçi D

  24. 72376

    Impact of Biologic and Oral Therapies on Systemic Inflammation in Psoriasis Measured by the Systemic Immune-Inflammation Index

    Johnsen N, Smart K, … senior author Armstrong A

  25. 72489

    Psoriasis Management in Individuals with Down Syndrome: A Retrospective Cohort Study Using the Epic Cosmos Dataset

    Rork J, Strohmeyer D, … senior author Burdick T

  26. 72640

    Enhanced effectiveness of guselkumab as first-line biologic therapy in psoriasis: real-world results over 84 weeks from the G-REAL study

    Gerdes S, Hoffmann M, … senior author von Kiedrowski R

  27. 72665

    Effectiveness, Safety, and Reduction of Systemic Inflammatory Response in Patients with Plaque Psoriasis Treated with Bimekizumab: A Real-Life Case Series

    Carrasco-Muñoz J, Albert-Cobo I, … senior author García-Fernández L

  28. 72716

    Guselkumab shows better long-term effectiveness and drug survival compared to secukinumab through 84 weeks in patients with moderate-to-severe plaque psoriasis - Results from the German non-interventional G-REAL study

    von Kiedrowski R, Gerdes S, … senior author Hoffmann M

  29. 72744

    Early and Maintained Treat-to-Target Response with Ixekizumab up to 5 Years in Moderate-to-Severe Psoriasis: A Post-Hoc Analysis of UNCOVER-3

    Armstrong A, Merola J, … senior author Pinter A

  30. 72762

    Efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis affecting the nails: A multicenter, randomized, double-blind, placebo-controlled, Phase 3b trial

    Yamauchi PS, Kerdel F, … senior author Sofen HL

  31. 72814

    Long-term (≥3 year) efficacy and safety of subcutaneous spesolimab for treatment of generalized pustular psoriasis: results from the EFFISAYIL program

    Gudjonsson JE, Navarini AA, … senior author Morita A

  32. 72841

    Sleep Quality, Duration, and Variability, and Their Relationship to Psoriatic Arthritis Disease Activity: A Pilot-Study

    Chada LP, Wang W, … senior author Merola J

  33. 72870

    Risk of superficial fungal infection in patients with psoriasis receiving Interleukin-17 inhibitors – A Propensity score-matched retrospective cohort study

    Li B, Sun C, … senior author Shu D

  34. 72884

    Automatic Psoriasis Area and Severity Index (PASI) assessment with AI-driven quantification

    Medela A, Dagnino D, … senior author Martorell A

  35. 72888

    APEX: Guselkumab Response and Inhibition of Structural Damage Progression in Active Psoriatic Arthritis by Participant Baseline Characteristics

    Mease PJ, Ritchlin CT, … senior author Rahman P

  36. 72909

    Bimekizumab durability of response through 4 years in patients with plaque psoriasis who stopped and re-started treatment

    Griffiths CEM, Costanzo A, … senior author Han G

  37. 72984

    Consistency of Skin Clearance With the Targeted Oral Peptide Icotrokinra: Results From a Large Pooled Cohort of Phase 3 Study Participants With Moderate-to-Severe Plaque Psoriasis

    Gold LS, Armstrong AW, … senior author Lebwohl MG

  38. 73014

    Real-world tildrakizumab persistence in the US by biologic experience and insurance coverage in the PPD CorEvitas Psoriasis Registry

    Lockshin B, Beeghly A, … senior author Prajapati VH

  39. 73017

    Regional differences in patient characteristics among US biologic initiators from the PPD CorEvitas Psoriasis Registry

    Prajapati VH, Blachley T, … senior author Lockshin B

  40. 73132

    Beyond Trial-and-Error: Mechanism-Guided Use of Biologics in Scalp Psoriasis

    Patra P

  41. 73136

    Risk of infections in patients with psoriasis treated with biologic agents and new oral small molecules. BIOBADADERM Registry

    Olivares-Guerrero M, Jiménez-Sánchez A, … senior author Daudén E

  42. 73163

    Representation of Race and Ethnicity in Randomized Control Trials of Biologic Therapies for Psoriasis: A Scoping Review

    Garcia S, Bosch L, … senior author Riley J

  43. 73228

    Durability of Response With Icotrokinra, a Targeted Oral Peptide, in Adults With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the Phase 3, Placebo- and Active Comparator-Controlled ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2 Trials

    Gold LS, Armstrong AW, … senior author Bissonnette R

  44. 73233

    Treatment of Plaque Psoriasis Involving High-Impact Sites With Icotrokinra, a Targeted Oral Peptide: Pooled Analyses of 4 Phase 3 Placebo-Controlled Trials

    Soung J, Armstrong AW, … senior author Gold LS

  45. 73312

    The development of a US patient-centric value framework in plaque psoriasis: psychological, emotional and social impacts of the disease

    Caloyeras J, Hyman J, … senior author Evans C

  46. 73341

    Effect of Risankizumab Versus Deucravacitinib on Psoriasis-Related Symptoms and Quality of Life in Patients With Moderate Plaque Psoriasis: Results From the IMMpactful Trial at Week 16

    Soung J, Magnolo N, … senior author Warren RB

  47. 73372

    A Mind-body Approach to Medicine: A Pilot Trial of Coach-Supported, Smartphone-Delivered Cognitive Behavioral Therapy for Psoriasis with Comorbid Depression

    Bensellam N, Barbieri J, … senior author Wilhelm S

  48. 73380

    Bimekizumab pharmacokinetics, safety, and efficacy in adolescents with moderate to severe plaque psoriasis: Data from the initial treatment period of the open-label BE CONNECTED phase 2 study

    Paller A, Szepietowski JC, … senior author Pinter A

  49. 73392

    Bimekizumab time to clinical response and achievement of clinically meaningful improvement thresholds in Chinese patients with psoriasis from the BE SHINING phase 3 trial

    Cai L, Man XY, … senior author Zhang J

  50. 73423

    Psoriasis epidemiology in patients with inflammatory bowel disease: A National Health Interview Survey Study

    Xiong D, Nassief G